The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis Based on Aggregate Data
Open accessAbstract
Purpose: This systematic review and meta-analysis were performed to assess the efficacy and tolerability of chemotherapy in patients with advanced gastric cancer. Methods: Randomized phase II and III clinical trials on first-line chemotherapy in advanced gastric cancer were identified by electronic searches of Medline, Embase, the Cochrane Controlled Trials Register, and Cancerlit; hand searches of relevant abstract books and reference lists; and contact to experts. Meta-analysis was performed using the fixed-effect model. Overall survival, reported as hazard ratio (HR) with 95% CI, was the primary outcome measure. Results: Analysis of chemotherapy versus best supportive care (HR = 0.39; 95% CI, 0.28 to 0.52) and combination versus single agent, mainly fluorouracil (FU) -based chemotherapy (HR = 0.83; 95% CI = 0.74 to 0.93) showed significant overall survival benefits in favor of chemotherapy and combination chemotherapy, respectively. In addition, comparisons of FU/cisplatin-containing regimens with versus without anthracyclines (HR = 0.77; 95% CI, 0.62 to 0.95) and FU/anthracycline-containing combinations with versus without cisplatin (HR = 0.83; 95% CI, 0.76 to 0.91) both demonstrated a significant survival benefit for the three-drug combination. Comparing irinotecan-containing versus nonirinotecan-containing combinations (mainly FU/cisplatin) resulted in a nonsignificant survival benefit in favor of the irinotecan-containing regimens (HR = 0.88; 95% CI, 0.73 to 1.06), but they have never been compared against a three-drug combination. Conclusion: Best survival results are achieved with three-drug regimens containing FU, an anthracycline, and cisplatin. Among these, regimens including FU as bolus exhibit a higher rate of toxic deaths than regimens using a continuous infusion of FU, such as epirubicin, cisplatin, and continuous-infusion FU.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The pyrimidine analogue 5-fluorouracil (5-FU) is a synthetic analogue of uracil that inhibits thymidylate synthase, limiting the availability of thymidine nucleotides for DNA synthesis (Figure 1b, Figure 2c). 5-FU and the related 5-FU-prodrug capecitabine remain widely used chemotherapies today and are an important treatment for gastrointestinal cancers (Heidelberger et al., 1957; Wagner et al., 2”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Wagner et al., 2006
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Practical Statistics for Medical Research.
Walter, S., & Altman, D. G. (1992) · Biometrics · doi:10.2307/2532320 · Cited by 11,666
Practical Statistics for Medical Research
Altman, D. G. (1990) · doi:10.1201/9780429258589 · Cited by 10,668
Chemotherapy for advanced gastric cancer
Wagner, D., Syn, N. L. X., Moehler, M. H., Grothe, W., Yong, W. P., Tai, B., Ho, J., & Unverzagt, S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004064.pub4 · Cited by 1,399
Self-citationSepulveda, C. R., Marlin, A., Yoshida, T., & Ullrich, A. (2002) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(02)00440-2 · Cited by 1,295
A Survey of Exact Inference for Contingency Tables
Agresti, A. (1992) · Statistical Science · doi:10.1214/ss/1177011454 · Cited by 1,132
Grothey, A., Sargent, D., Goldberg, R. M., & Schmoll, H.-J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.037 · Cited by 1,070
Self-citationWebb, A., Cunningham, D., Scarffe, J. H., Harper, P., Norman, A. R., Joffe, J., Hughes, M., Mansi, J., Findlay, M., Hill, A., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.261 · Cited by 868
Glimelius, B. L. G., Ekström, K., Hoffman, K., Graf, W. D., Sjödén, P., Haglund, U., Svensson, C., Enander, L. K., Linné, T., Sellsröm, H., et al. (1997) · Annals of Oncology · doi:10.1023/a:1008243606668 · Cited by 844
Pyrhönen, S. O., Kuitunen, T., Nyandoto, P., & Kouri, M. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.114 · Cited by 786
Systematic reviews of evaluations of prognostic variables
Altman, D. G. (2001) · BMJ · doi:10.1136/bmj.323.7306.224 · Cited by 756
Flagged first, then by citations
Research works printed but not linked: 1
- 10.1001/jama.1985.03350380077025 · DOI
Cited by
Sorted by citations
Items 401–500 of 1,000
Paclitaxel induces autophagy in gastric cancer BGC823 cells
Yu, Y., Hu, P., Wang, Y., Xu, X., Rushworth, G.-M., Zhang, Z., Wei, L., & Zhang, J. (2017) · Ultrastructural Pathology · doi:10.1080/01913123.2017.1334019 · Cited by 26
“Chemotherapy remains the mainstay of treatment for metastatic and locally advanced gastric cancer, and has been associated with improved quality of life and survival in patients with advanced disease [3].”
BackgroundOxaliplatin induces muscle loss and muscle‐specific molecular changes in Mice
Feather, C. E., Lees, J. G., Makker, P. G. S., Goldstein, D., Kwok, J. B., Moalem‐Taylor, G., & Polly, P. (2017) · Muscle & Nerve · doi:10.1002/mus.25966 · Cited by 26
Wang, X., Yan, S., Dai, W., Liu, X., Zhang, W., & Wang, J. (2010) · International Journal of Cancer · doi:10.1002/ijc.25294 · Cited by 26
“Chemotherapy with cytotoxic drugs plays an essential role in the management of advanced gastric cancer.(1) However, not all patients with gastric cancer respond well to the cytotoxic drugs.”
BackgroundS-1-based therapy versus 5-FU-based therapy in advanced gastric cancer: a meta-analysis
Huang, J., Cao, Y., Wu, L., Liao, C., He, Y., & Gao, F. (2010) · Medical Oncology · doi:10.1007/s12032-010-9594-0 · Cited by 25
“[25] conducted a meta-analysis of che-”
Wang, J., Qu, J., Li, Z., Che, X., Zhang, J., Liu, J., Teng, Y., Jin, B., Zhao, M., Liu, Y., et al. (2016) · Translational Oncology · doi:10.1016/j.tranon.2016.04.004 · Cited by 25
“Palliative chemotherapy is still a major treatment in metastatic or recurrent gastric cancer [3,4].”
BackgroundDong, X., Chen, R., Lin, H., Lin, T., & Pan, S. (2018) · Medical Science Monitor · doi:10.12659/msm.905965 · Cited by 25
Zhao, S., Shao, L., Wang, Y., Meng, Q., & Yu, J. (2019) · Archives of Medical Science · doi:10.5114/aoms.2019.85146 · Cited by 25
“Accumulating evidence suggests that different signalling pathways are implicated in the development of GC and induction of resistance against drugs [8].”
BackgroundKundel, Y., Sternschuss, M., Moore, A., Perl, G., Brenner, B., & Goldvaser, H. (2020) · Cancer Medicine · doi:10.1002/cam4.3417 · Cited by 24
Santero, M., Bracchiglione, J., Acosta‐Dighero, R., Meade, A.-G., Antequera, A., Auladell-Rispau, A., Quintana, M. J., Requeijo, C., Rodríguez-Grijalva, G., Salas-Gama, K., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08330-5 · Cited by 25
“The use of systemic oncological treatments (SOT) has been widely investigated for esophageal and gastric cancers, and as a consequence, chemotherapy (CT), targeted therapy, and immunotherapy are largely used to try to improve survival and quality of life (QoL) [8, 9].”
BackgroundPathologic Diagnostics of HER2 Positivity in Gastroesophageal Adenocarcinoma
Koopman, T., Louwen, M., Hage, M., Smits, M. M., & Imholz, A. L. T. (2015) · American Journal of Clinical Pathology · doi:10.1309/ajcpcx69hgddgycq · Cited by 25
Latest developments and emerging treatment options in the management of stomach cancer
Delaunoit, T. (2011) · Cancer Management and Research · doi:10.2147/cmar.s12713 · Cited by 25
Galdy, S., Cella, C. A., Spada, F., Murgioni, S., Frezza, A. M., Ravenda, S. P., Zampino, M. G., & Fazio, N. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.09.004 · Cited by 25
Park, S., Ha, S., Kwon, H. W., Kim, W. H., Kim, T., Oh, D., Cheon, G. J., & Bang, Y. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.182675 · Cited by 25
Clinically Applicable Inhibitors Impacting Genome Stability
Prakash, A., García-Moreno, J. F., Brown, J. A. L., & Bourke, E. (2018) · Molecules · doi:10.3390/molecules23051166 · Cited by 24
Yu, J., Gao, J., Lü, Z., Li, Y., & Shen, L. (2012) · Medical Oncology · doi:10.1007/s12032-012-0292-y · Cited by 25
“Randomized studies demonstrated that compared with best-supportive care, chemotherapy can improve patient’s survival and quality of life [4].”
BackgroundSundar, R., Chia, D. K. A., Zhao, J., Lee, A. R. Y. B., Kim, G., Tan, H. L., Pang, A., Shabbir, A., Willaert, W., Ma, H., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103681 · Cited by 25
Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer
Lauro, L. D., Vici, P., Belli, F., Tomao, S., Fattoruso, S. I., Arena, M. G., Pizzuti, L., Giannarelli, D., Paoletti, G., Barba, M., et al. (2013) · Gastric Cancer · doi:10.1007/s10120-013-0321-3 · Cited by 24
“The role of chemotherapy was further confirmed in a meta-analysis, which also suggested that three-drug combinations conferred longer survival compared to monochemotherapy and doublets [6].”
ResultMetastatic gastric cancer – focus on targeted therapies
Meza–Junco, J., & Sawyer, M. B. (2012) · Biologics · doi:10.2147/btt.s23917 · Cited by 24
“Using combination chemotherapy results in a median OS of 9–14 months.(3) There is no international consensus regarding the optimal first-line chemotherapy regimen, however a platinum plus fluoropyrimidine doublet or a triplet regimen with the addition of epirubicin or docetaxel are most frequently used.”
Wang, S., Chen, J., Xu, C., Cao, W., Cai, R., Cao, L., & Cai, G. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1040495 · Cited by 24
Chen, W., Wang, F., & Xu, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068974 · Cited by 24
Zhong, H., Zhang, Y., Ma, S., Ying, J.-E., Yang, Y., Yong, D., Hang, X., Sun, Q., Zhong, B., & Wang, D. (2008) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328314b5ab · Cited by 24
Ocvirk, J., Reberšek, M., Škof, E., Hlebanja, Z., & Boc, M. (2011) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e31820dc0b0 · Cited by 24
“Treatment with epirubicin, cisplatin, and continuous infusion 5-FU (ECF) has shown survival advantage compared with various nonanthracycline-containing fluoropyrimidine combinations.(5,6,8,10) In phase II studies, the ECF regimen resulted in response rates greater than 50%, with moderate toxicity.”
ResultSaito, M., Kiyozaki, H., Takata, O., Suzuki, K., & Rikiyama, T. (2014) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-12-406 · Cited by 24
“The current standard treatment for stage IV gastric cancer is systemic chemotherapy [6,7].”
BackgroundBrieau, B., Auzolle, C., Pozet, A., Tougeron, D., Bouché, O., Soibinet, P., Coriat, R., Prieux, C., Lecomte, T., Goujon, G., et al. (2015) · Digestive and Liver Disease · doi:10.1016/j.dld.2015.12.012 · Cited by 25
Targeted therapy for advanced gastric cancer: A review of current status and future prospects
Kanat, Ö., O’Neil, B. H., & Shahda, S. (2015) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v7.i12.401 · Cited by 24
Wu, J., Jin, R., Xia, Y., Chen, Q., Li, W., Chen, D., Ye, H., Zhao, C., Du, X., Shi, D., et al. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s90081 · Cited by 26
“Chemotherapy is an important treatment option for gastric cancer patients besides surgical resection.(2) However, chemotherapy has two main issues that affect the treatment of gastric cancer patients: the resistance of tumor tissue against chemotherapeutic drugs and the toxicity of these drugs to normal tissue.”
Tantoy, I. Y., Dhruva, A., Cataldo, J. K., Venook, A. P., Cooper, B. A., Paul, S. M., Levine, J. D., Conley, Y. P., Cartwright, F., Lee, K. A., et al. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2017.01.09 · Cited by 23
NFATc3 mediates the sensitivity of gastric cancer cells to arsenic sulfide
Zhang, X., Kang, T., Zhang, L., Tong, Y., Ding, W., & Chen, S. (2017) · Oncotarget · doi:10.18632/oncotarget.17175 · Cited by 24
“However, the mainstay therapy for the advanced stage GC is systemic chemotherapy, with the 5-year overall survival less than 20% [3].”
BackgroundKim, B. G., Oh, S. Y., Kwon, H.-C., Lee, S., Lee, D. M., Kim, S.-G., Kim, D.-K., Jang, J. S., Kim, M. C., Kim, S., et al. (2010) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e3181a650d4 · Cited by 23
“93) demonstrated significant overall survival (OS) results in favor of chemotherapy and combination chemotherapy.(4,5) Several chemotherapeutic drugs, including 5-FU, mitomycin C, nitrosoureas, and doxorubicin have evidenced some level of efficacy against advanced gastric cancer.”
BackgroundLordick, F. (2011) · Future Oncology · doi:10.2217/fon.10.178 · Cited by 23
“Overview of the market A need for better treatment The most commonly used regimens to treat gastric cancer are a fluoropyrimidine (capecitabine or 5‐fluorouracil [5‐FU]) and a platinum agent (cisplatin or oxaliplatin) alone or in combination with an anthracy‐ cline [4–6,103].”
BackgroundPark, S., Nam, C. M., Kim, S., Mun, J. E., Rha, S. Y., & Chung, H. C. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.10.030 · Cited by 25
Monoclonal antibodies in gastrointestinal cancers
Bronte, G., Cicero, G., Cusenza, S., Galvano, A., Musso, E., Rizzo, S., Sortino, G., Roselli, M., Bazan, V., Fiorentino, E., et al. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.774367 · Cited by 23
“4 Trastuzumab Chemotherapy improved survival compared to BSC in patients with advanced gastric cancer (GC) and combination chemotherapy was superior to monotherapy [41].”
BackgroundSeom guidelines for the treatment of gastric cancer 2015
Martín-Richard, M., Custodio, A., Girón, C. G., Grávalos, C., Gomez, C. N., Jiménez‐Fonseca, P., Manzano, J. L., Pericay, C., Rivera, F., & Carrato, A. (2015) · Clinical & Translational Oncology · doi:10.1007/s12094-015-1456-y · Cited by 23
“Several randomized studies and a meta-analysis [47], comparing palliative CT with the best supportive care (BSC), have demonstrated that CT increases median overall survival and improves the quality of life of patients with advanced gastric cancer [I,A].”
ResultWang, X., Zhang, R., Du, N., Yang, M., Zang, A., Liu, L., Yu, J., Gao, J., Zhang, J., Fu, Z., et al. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920905424 · Cited by 23
Liu, C., Sun, Q., Hang, X., Zhong, B., & Wang, D. (2008) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32830c457e · Cited by 23
Liu, J. (2011) · World Journal of Gastroenterology · doi:10.3748/wjg.v17.i2.181 · Cited by 23
Recinos, V. R., Bekelis, K., Ziegler, S. G., Vick, D., Hertig, S., Tyler, B., Li, K. W., Kosztowski, T. A., Legnani, F. G., Brem, H., et al. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9984-3 · Cited by 23
Jeung, J. A., Patel, R., Vila, L., Wakefield, D. N., & Liu, C. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2011-0371-oa · Cited by 22
“Improvements in the treatment of gastric cancer, including combination chemotherapy, have resulted in improved overall survival versus single-agent chemotherapy alone.(6)”
BackgroundSun, D. S., Jeon, E. K., Won, H. S., Park, J. C., Shim, B. Y., Park, S. Y., Hong, Y. S., Kim, H. K., & Ko, Y. H. (2014) · Gastric Cancer · doi:10.1007/s10120-014-0405-8 · Cited by 22
“A meta-analysis that compared systemic single therapy with combination treatment found that combination treatment was associated with a significantly greater response rate [19].”
BackgroundCarmona‐Bayonas, A., Jiménez‐Fonseca, P., Sánchez‐Lorenzo, L., Ramchandani, A., Asensio, E., Custodio, A. B., Marcelo Garrido, S., Echavarría, I., Cano, J. M., Barreto, J. E. L., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0148 · Cited by 22
“J Natl Compr Canc Netw 2016;14(11):1379–1388”
Özdemir, N., Abalı, H., Öksüzoğlu, B. Ç., Budakoğlu, B., Uncu, D., Güler, T., Odabaşı, H., & Zengin, N. (2009) · Medical Oncology · doi:10.1007/s12032-009-9268-y · Cited by 22
“[6] including phase 2 and 3 studies for the primary treatment of metastatic gastric cancer, both monotherapy and combined chemotherapy were found to be superior to BCS alone.”
BackgroundCao, W., Weiping, Y., Lou, G., Jiang, J., Geng, M., Xi, W., Li, H., Ma, T., & Ye-ning, J. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3283273509 · Cited by 22
Prognostic Significance of Non-curative Gastrectomy for Incurable Gastric Carcinoma
Jeong, O., Park, Y. K., Choi, W. Y., & Ryu, S. Y. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3638-1 · Cited by 22
Eastern Canadian Colorectal Cancer Consensus Conference: Setting the Limits of Resectable Disease
Vickers, M. M., Samson, B., Colwell, B., Cripps, C., Jalink, D., El-Sayed, S. M., Chen, E., Porter, G. A., Goel, R., Villeneuve, J., et al. (2010) · Current Oncology · doi:10.3747/co.v17i3.610 · Cited by 22
Gastric cancer: The times they are a-changin’
Satolli, M. A. (2015) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v7.i11.303 · Cited by 22
Primary Tumor Resection and Survival in Patients with Stage IV Gastric Cancer
Müsri, F. Y., Mutlu, H., Karaağaç, M., Eryılmaz, M. K., Gunduz, S. G., & Artaç, M. (2016) · Journal of the Korean Gastric Cancer Association · doi:10.5230/jgc.2016.16.2.78 · Cited by 22
“In this patient group, the OS rate is 3~5 months with best supportive care and 9~11 months with chemotherapy.(8) If there is human epidermal growth factor receptor-2 overexpression, trastuzumab can be added to the therapy, increasing the survival rate to 11~14 months.”
BackgroundCost‐Effectiveness Analysis of Second‐Line Chemotherapy Agents for Advanced Gastric Cancer
Lam, S. W., Wai, M., Lau, J. E., McNamara, M. J., Earl, M. A., & Udeh, B. L. (2016) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1870 · Cited by 22
“advanced or metastatic gastric cancer.(2) However, for those who fail first-line therapy, outcomes remain poor, with an estimated survival less than 6 months.”
BackgroundSun, Z., Cheng, X., Ge, Y., Shao, L., Xuan, Y.-H., & Yan, G. (2017) · Gastric Cancer · doi:10.1007/s10120-017-0763-0 · Cited by 22
“1 3 reviews have reached a consensus to propose the ECF regimen as standard care [25].”
BackgroundQi, W., Sun, L., Liu, N., Zhao, S., Lv, J., & Qiu, W. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9360 · Cited by 22
“However, the majority of gastric cancer cases are diagnosed in the middle to late stage (6).”
BackgroundNew drug developments in metastatic gastric cancer
Tan, A. C., Chan, D. L. H., Faisal, W., & Pavlakis, N. (2018) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284818808072 · Cited by 22
Wu, X., Shen, J., Xiao, Z., Li, J., Zhao, Y., Zhao, Q., Cho, C. H., & Li, M. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.03.011 · Cited by 22
Moon, Y. W., Rha, S. Y., Jeung, H., Kim, C., Hong, M. H., Chang, H. K., Roh, J. K., Noh, S. H., Kim, B., & Chung, H. C. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1295-z · Cited by 22
“Although a recent metaanalysis showed combination therapy was better than monotherapy in terms of RR and OS [31], in our study, prolongation of PFS with the second-line combination over monotherapy was not translated into OS.”
ResultLin, J.-X., Yoon, C., Li, P., Ryeom, S. W., Cho, S., Zheng, C., Xie, J., Wang, J.-B., Lu, J., Chen, Q., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0963-y · Cited by 21
RetractedSynergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells
Shi, M., Lou, B.-X., Ji, J., Shi, H., Zhou, C., Yu, Y., Liu, B., Zhu, Z., & Zhang, J. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2166-1 · Cited by 21
“[22] conducted a meta-analysis and reported a hazard ratio (HR) of 0.”
MethodKim, J. G., Sohn, S. K., Chae, Y. S., Song, H. S., Kwon, K.-Y., R, Y., Kim, M.-K., Lee, K. H., Hyun, M. S., Ryoo, H. M., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604188 · Cited by 21
“However, in a recent meta-analysis of randomised phase II and phase III studies best survival results were achieved with three-drug regimens containing 5-FU, an anthracycline, and cisplatin in patients with advanced gastric cancer (Wagner et al, 2006).”
BackgroundPernot, S., Mitry, E., Samalin, E., Dahan, L., Dalban, C., Ychou, M., Seitz, J., Turki, H., Mazard, T., Zaanan, A., et al. (2013) · Gastric Cancer · doi:10.1007/s10120-013-0266-6 · Cited by 21
“of limited duration and tolerability varies according to the therapeutic protocol [1].”
BackgroundHultman, B., Lundkvist, J., Glimelius, B. L. G., Nygren, P., & Mahteme, H. (2011) · Acta Oncologica · doi:10.3109/0284186x.2011.594809 · Cited by 21
Komori, S., Osada, S., Tanaka, Y., Takahashi, T., Nagao, N., Yamaguchi, K., Asano, N., & Yoshida, K. (2010) · Rare Tumors · doi:10.4081/rt.2010.e5 · Cited by 21
Zhang, X., Chen, X., Wu, T., Zhang, Y., Yan, K., & Sun, X. (2015) · PubMed · Cited by 21
Ramucirumab: A New Therapy for Advanced Gastric Cancer
Oholendt, A. L., & Zadlo, J. L. (2015) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2015.6.1.8 · Cited by 21
“Chemotherapy is the primary modality for management of advanced and metastatic gastric cancers and has been shown to improve quality of life and prolong survival (Wagner et al., 2006).”
BackgroundYamaguchi, K., Fujitani, K., Nagashima, F., Omuro, Y., Machida, N., Nishina, T., Koue, T., Tsujimoto, M., Maeda, K., & Satoh, T. (2018) · Gastric Cancer · doi:10.1007/s10120-018-0811-4 · Cited by 21
Wen, L., Li, Y., Zhang, J., Zhou, C., Yang, H.-N., Chen, X., Xu, L., Kong, S., Wang, X., & Zhang, H. (2019) · Future Oncology · doi:10.2217/fon-2019-0039 · Cited by 21
Wang, T., Gao, J., Yu, J., & Shen, L. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.1000-9604.2013.08.14 · Cited by 21
Shitara, K., Matsuo, K., Mizota, A., Kondo, C., Nomura, M., Takahari, D., Yokota, T., Ura, T., Ito, S., Sawaki, A., et al. (2011) · Gastric Cancer · doi:10.1007/s10120-011-0019-3 · Cited by 21
“analysis [16] have demonstrated the efficacy of each of these agent classes as first-line chemotherapy, to our knowledge this is the first study to simultaneously evaluate exposure to each agent class in all lines of treatment.”
BackgroundBeyond anticoagulant: Heparin as a potential anti-cancer agent
Lokwani, R., Azmi, N. S., Yusoff, M. M., & Ichwan, S. J. A. (2014) · Journal of Biochemistry Microbiology and Biotechnology · doi:10.54987/jobimb.v2i2.160 · Cited by 20
“inhibit the activity of βFGF [93-94].”
BackgroundGómez‐Ulloa, D., Amonkar, M. M., Kothari, S., Cheung, W. Y., Chau, I., Zalcberg, J. R., Suriñach, N. L., & Falcone, A. (2020) · BMC Gastroenterology · doi:10.1186/s12876-020-01232-z · Cited by 20
Li, J., Han, T., Wang, X., Wang, Y., Xuan, C., Chen, W., & Yang, Q. (2022) · World Journal of Surgical Oncology · doi:10.1186/s12957-022-02760-6 · Cited by 20
“The majority of GC patients are diagnosed in the middle to late stage and therefore lose the opportunity to be cured [4].”
BackgroundZhang, X., Zhang, C., Hou, H., Zhang, Y., Jiang, P., Zhou, H., Wang, L., Zhou, N., & Zhang, X. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101657 · Cited by 20
Wang, S., Chang, Y., Liu, T., Huang, K., Fang, W., Li, A. F., Yeh, T., Hung, G., & Lee, H. (2023) · FEBS Journal · doi:10.1111/febs.16992 · Cited by 20
“In advanced gastric cancers, the median overall survival is approximately 6 months [9].”
BackgroundXia, Y., Weng, B., Wang, Z., Kang, Y., Shi, L., Huang, G., Ying, S., Du, X., Chen, Q., Jin, R., et al. (2015) · Tumor Biology · doi:10.1007/s13277-015-4277-2 · Cited by 20
“Thus, chemotherapy is still very important especially for patients with recurrence and metastasis [1].”
BackgroundWang, W., Fang, C., Wang, X., Chen, Y., Wang, Y., Feng, W., Yan, C., Zhao, M., & Peng, S. (2013) · Nanoscale · doi:10.1039/c3nr00227f · Cited by 20
Schønnemann, K. R., Jensen, H. A., Yilmaz, M. K., Jensen, B. V., Larsen, O., & Pfeiffer, P. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604569 · Cited by 20
“Data from randomised studies have shown that combination chemotherapy results in a significant survival advantage and improves quality of life in patients with advanced GC (Murad et al, 1993; Pyrhonen et al, 1995; Glimelius et al, 1997; Wagner et al, 2006).”
BackgroundAmarantidis, K., Xenidis, N., Chelis, L., Chamalidou, E., Dimopoulos, P., Michailidis, P., Tentes, A.-A. K., Deftereos, S. P., Karanikas, M., Karayiannakis, A. J., et al. (2011) · Oncology · doi:10.1159/000330199 · Cited by 20
“There is no globally accepted standard chemotherapy regimen for those patients; therefore, the need for more effective systemic therapy is urgent. Combination chemotherapy seems to be more advantageous than monotherapy [”
BackgroundGao, Y., Zhang, H., Yang, S., YANG, Y., Ma, Y., Zhang, X., & Yang, Y. (2014) · Oncology Reports · doi:10.3892/or.2014.2994 · Cited by 20
“Unfortunately, there is no internationally accepted standard chemotherapy for advanced gastric cancer, and uncertainty remains regarding the choice of the optimal regimen (5,6).”
BackgroundRecent advances in chemotherapy for advanced gastric cancer
Kim, J. G. (2010) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v2.i7.287 · Cited by 20
Preoperative chemotherapy with S-1 and cisplatin for highly advanced gastric cancer.
Nashimoto, A., Yabusaki, H., Nakagawa, S., Takii, Y., Tsuchiya, Y., & Tanaka, O. (2009) · PubMed · Cited by 20
Selçukbırıcık, F. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i14.2154 · Cited by 20
Targeted therapies in gastric cancer treatment: where we are and where we are going
Tomasello, G., Ghidini, M., Liguigli, W., Ratti, M., Toppo, L., & Passalacqua, R. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0330-2 · Cited by 20
“In the advanced setting, a number of meta-analyses have clearly demonstrated the survival benefit associated with chemotherapy compared with supportive care alone and the superiority of combination chemotherapy over therapy with 5FU single agent [3, 4].”
BackgroundAndus, T., Anthuber, M., Arends, J., Arnold, D., Aust, D., Baier, P. K., Baretton, G. B., Bernhardt, J., Boeing, H., Böhle, E., et al. (2011) · Cited by 20
Self-citationChemo-Immunotherapy Using Lentinan for the Treatment of Gastric Cancer with Liver Metastases
Ina, K., Furuta, R., Kataoka, T., Kayukawa, S., Ina, H., & Yoneda, M. (2016) · Medical Sciences · doi:10.3390/medsci4020008 · Cited by 20
Sodium Selenite Inhibits Proliferation of Gastric Cancer Cells by Inducing SBP1 Expression
Gong, J., & Li, L. (2016) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.239.279 · Cited by 20
“Despite recent advances in the diagnosis and treatment of gastric cancer, the prognosis of individuals with an advanced stage of disease remains poor and treatment options mainly focus on surgery and chemoradiotherapy (Wagner et al. 2006).”
BackgroundSatake, H., Miki, A., Kondo, M., Kotake, T., Okita, Y., Hatachi, Y., Yasui, H., Imai, Y., Ichikawa, C., Murotani, K., et al. (2017) · ESMO Open · doi:10.1136/esmoopen-2016-000130 · Cited by 20
“DLT was defined as any of the following adverse events occurring in the neoadjuvant chemotherapy period: (1) grade 4 neutropaenia lasting>4 days; (2) grade 4 thrombocytopaenia (<25×109/L); (3) febrile neutropaenia; (4) grade 3 or 4 non-haematological toxic effects; (5) a treatment delay longer than 14 days due to drug…”
BackgroundManagement of Metastatic Gastric Cancer
Obermannova, R. L., & Lordick, F. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.01.006 · Cited by 20
AGAMENON study group, Carmona‐Bayonas, A., Jiménez‐Fonseca, P., Custodio, A., Cánovas, M. S., Hernández, R., Pericay, C., Echavarría, I., Lacalle, A., Visa, L., et al. (2017) · Gastric Cancer · doi:10.1007/s10120-017-0718-5 · Cited by 20
Uemura, N., Kikuchi, S., Sato, Y., Ohnuma, H., Okamoto, K., Miyamoto, H., Hirakawa, M., Sagawa, T., Fujikawa, K., Takahashi, Y., et al. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3404-8 · Cited by 20
Kim, J. W., Kim, J. G., Kang, B. W., Chung, I., Hong, Y. S., Kim, T., SONG, H. S., Lee, K. H., Zang, D. Y., Ko, Y. H., et al. (2018) · Cancer Research and Treatment · doi:10.4143/crt.2018.073 · Cited by 20
Nishida, T., Sugimoto, A., Tomita, R., Higaki, Y., Osugi, N., Takahashi, K., Mukai, K., Matsubara, T., Nakamatsu, D., Hayashi, S., et al. (2019) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v11.i1.28 · Cited by 20
Discoidin domain receptor 1 activity drives an aggressive phenotype in bladder cancer.
Xie, X., Rui, W., He, W., Shao, Y., Sun, F., Zhou, W., Wu, Y., & Zhu, Y. (2017) · Europe PMC (PubMed Central) · Cited by 20
Gao, Z., Ni, J., Ding, H., Yan, C., Ren, C., Li, G., Pan, F., & Jin, G. (2020) · Cancer Medicine · doi:10.1002/cam4.3215 · Cited by 20
Kang, B. W. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i18.5396 · Cited by 20
Shitara, K., Ito, S., Misawa, K., Ito, Y., Ito, H. M., Hosono, S., Watanabe, M., Tajima, K., Tanaka, H., Muro, K., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr293 · Cited by 20
“The prognosis of patients with unresectable or recurrent gastric cancer remains poor, as chemotherapy confers only a minimal survival advantage, with a median survival of 1 year [5, 6].”
BackgroundOptimising treatment regimens for the management of advanced gastric cancer
Wong, R., & Cunningham, D. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp203 · Cited by 20
“Combination chemotherapy results in superior outcomes compared with monotherapy [2] and several large randomised controlled trials have been conducted over the past few decades in an attempt to define the optimal first-line regimen.”
BackgroundResultTargeting deficient DNA damage repair in gastric cancer
Young, K., Starling, N., & Cunningham, D. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1217992 · Cited by 20
Chemotherapy for Advanced Gastric Cancer
Al‐Batran, S., Jäger, E., & Scholz, M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.4896 · Cited by 20
Shen, J., Wei, J., Wang, H., Yang, Y., Yue, G., Wang, L., Yu, L., Xie, L., Sun, X., Bian, X., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075564 · Cited by 19
“Gastric cancer is one of the most frequent causes of cancerrelated death worldwide [1,2].”
BackgroundTaxanes in the Treatment of Advanced Gastric Cancer
Kang, B., Kwon, O., Chung, H. Y., Yu, W., & Kim, J. G. (2016) · Molecules · doi:10.3390/molecules21050651 · Cited by 19
“Although rapid advances in treatment options have improved the prognosis of advanced gastric cancer (AGC), it remains a major public health problem and the second leading cause of cancer-related deaths in the world [1,2].”
BackgroundTang, Q., Sun, J., Yu, H., Shi, X., Lv, R., Hong-chang, W., & Yin, P.-H. (2016) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2016/8203789 · Cited by 20
“Efficacy rates of 50% have been reported for chemotherapy drugs, such as cisplatin (DDP), which are widely used in clinical settings [2, 3].”
BackgroundPetrillo, A., Laterza, M. M., Tirino, G., Pompella, L., Ventriglia, J., Pappalardo, A., Famiglietti, V., Martinelli, E., Ciardiello, F., Orditura, M., et al. (2018) · Future Oncology · doi:10.2217/fon-2018-0167 · Cited by 19
Liao, Y., Chen, W., Shi, W., & Zha, H.-L. (2021) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-021-04322-1 · Cited by 19
“Because the majority of patients with gastric cancer present with metastatic disease and nearly all patients develop chemotherapy resistance [22], our findings may contribute to improved control of gastric cancer patients.”
BackgroundTan, Y. C., Wang, H., Xu, B., Zhang, X., Zhu, G., Ge, Y., Lu, T., Gao, R., & Li, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.977708 · Cited by 19
Metadata
- Authors
- Wagner, A. D., Grothe, W., Haerting, J., Kleber, G., Grothey, A., & Fleig, W. E.
- Affiliations
- From the First Department of Medicine, Coordinating Centre for Clinical Trials, Department of Medicine IV, and Institute of Medical Epidemiology, Biostatistics and Informatics, Martin-Luther-University Halle-Wittenberg, Halle/Saale, Germany; and Mayo Clinic College of Medicine, Rochester, MN
- Mayo Clinic (US)
- Venue
- Journal of Clinical Oncology
- Published
- 2006-06-20
- Volume
- 24
- Issue
- 18
- Pages
- 2903-2909
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2145390243
- Cited by
- 1,171
- References
- 51
- Citations by year
- 2026: 7 · 2025: 15 · 2024: 26 · 2023: 28 · 2022: 34 · 2021: 64 · 2020: 55 · 2019: 54 · 2018: 69 · 2017: 89 · 2016: 72 · 2015: 84 · 2014: 105 · 2013: 92 · 2012: 77
- FWCI
- 9.54
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Society of Clinical Oncology
- Bundesministerium für Bildung und Forschung (01GH0105)
- Topics
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
- Keywords
- advanced gastric cancer, first-line chemotherapy, 5-fluorouracil, cisplatin, anthracyclines, irinotecan, combination chemotherapy, overall survival, best supportive care, epirubicin, chemotherapy toxicity
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Humans, Stomach Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
